Home > Boards > US Listed > Medical - Drugs > Humanigen Inc. (HGEN)

LLY Monoclonal Antibody + Remidesivir Halted on Safety-

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Fezziwig2008 Member Profile
 
Followed By 26
Posts 501
Boards Moderated 1
Alias Born 03/09/14
160x600 placeholder
アジア太平洋地域での成長計画を促進すべくHumanigen Australia Proprietary Limitedを設立 Business Wire - 11/25/2020 11:01:00 AM
Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans Business Wire - 11/23/2020 4:05:00 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 11/20/2020 6:04:41 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/12/2020 4:17:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2020 6:07:48 AM
Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results Business Wire - 11/11/2020 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/10/2020 4:54:34 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/6/2020 9:14:09 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2020 9:06:44 AM
Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab™ in Patients Hospitalized with COVID-19 Business Wire - 11/6/2020 7:00:00 AM
Humanigen Announces Cooperative Research & Development Agreement with the Department of Defense to Develop Lenzilumab for COV... Business Wire - 11/6/2020 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/4/2020 5:01:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2020 4:46:15 PM
Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting Business Wire - 11/4/2020 4:05:00 PM
Humanigen Executes Licensing Agreement for Lenzilumab™ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea &... Business Wire - 11/3/2020 7:30:00 AM
Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVI... Business Wire - 10/30/2020 2:05:00 PM
Humanigen Announces First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab™ for COVID-19 Business Wire - 10/29/2020 7:00:00 AM
Humanigen to Present at Upcoming Investor Conferences Business Wire - 10/27/2020 4:01:00 PM
National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential... Business Wire - 10/13/2020 11:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/7/2020 4:31:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/7/2020 4:30:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 4:14:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 4:08:22 PM
Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution & Discharge after Single IND Emergency Use Authorizat... Business Wire - 10/2/2020 8:00:00 AM
Humanigen Announces Lenzilumab in COVID-19 Program Updates Business Wire - 10/2/2020 7:00:00 AM
Fezziwig2008   Tuesday, 10/13/20 07:43:01 PM
Re: None
Post # of 22183 
LLY Monoclonal Antibody + Remidesivir Halted on Safety- - Helps $HGEN’s BET trial case- “Lilly’s ACTIV-3 trial is intended to test a monoclonal antibody developed in partnership with Gilead Sciences' remdesivir, an antiviral drug granted emergency use authorization by the U.S. Food and Drug Administration to treat COVID-19 infections”

https://www.actionnewsjax.com/news/trending/eli-lilly-pauses-late-stage-covid-19-antibody-treatment-trial-amid-safety-concerns/V3LLTEPZNBEDDADEBWFZFH7Q5Y/?outputType=amp

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences